Benzinga
Privately-held Morphogenesis Inc has agreed to combine with CohBar Inc (NASDAQ: CWBR) in an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline. The combined company will focus on advancing Morphogenesis' two technologies that seek to overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer. The combined company is expected to operate under the name "TuHURA Biosciences Inc" and to trade